Genmab A/S logo
Genmab A/S GMAB
$ 50.36 -1.64%
report update icon

Quarterly report 2022-Q4
added 11-18-2026

Genmab A/S Revenue | GMAB

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Genmab A/S

2025 2024 2023 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - - 10.1 B 5.37 B 3.03 B 2.37 B 1.82 B 1.13 B 850 M 664 M 485 M 351 M

All numbers in DKK currency

Indicator range from annual reports

Maximum Minimum Average
10.1 B 351 M 2.62 B

Quarterly Revenue Genmab A/S

2025-Q4 2025-Q2 2024-Q4 2024-Q2 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1
- - 21.5 B 5.4 B 16.5 B 4.2 B - - 3.16 B - - - 1.97 B - - - 5.45 B - - - 774 M - - - 510 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in DKK currency

Indicator range from quarterly reporting

Maximum Minimum Average
21.5 B 510 M 6.61 B

References

  1. Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer Revenue Price % 24h Market Cap Country
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
109 K $ 1.52 -8.16 % $ 9.72 B australiaAustralia
Shineco, Inc. Shineco, Inc.
TYHT
23.7 M - -3.90 % $ 97.2 M chinaChina
Certara Certara
CERT
419 M $ 10.56 -1.12 % $ 1.69 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
113 M $ 13.26 -0.15 % $ 190 M usaUSA
Processa Pharmaceuticals Processa Pharmaceuticals
PCSA
5 K $ 1.59 -5.92 % $ 2.08 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
761 M $ 63.61 -2.11 % $ 6.61 B usaUSA
Progenity, Inc. Progenity, Inc.
PROG
74.3 M - -3.47 % $ 164 M usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
30.7 M - 1.52 % $ 136 M usaUSA
Nektar Therapeutics Nektar Therapeutics
NKTR
55.2 M $ 30.23 -7.1 % $ 510 M usaUSA
Innate Pharma S.A. Innate Pharma S.A.
IPHA
9 M $ 0.87 -7.57 % $ 77.9 M franceFrance
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
13.5 K - -1.19 % $ 28.7 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
3.22 B $ 60.42 -1.64 % $ 11.6 B usaUSA
Matinas BioPharma Holdings Matinas BioPharma Holdings
MTNB
1.1 M $ 0.75 -9.23 % $ 4.11 M usaUSA
Enanta Pharmaceuticals Enanta Pharmaceuticals
ENTA
63 M $ 7.6 -4.82 % $ 220 M usaUSA
Lipocine Lipocine
LPCN
1.98 M $ 1.47 -2.33 % $ 8.01 M usaUSA
Seres Therapeutics Seres Therapeutics
MCRB
789 K $ 1.25 -6.02 % $ 11.1 M usaUSA
Oramed Pharmaceuticals Oramed Pharmaceuticals
ORMP
2 M $ 3.58 -2.98 % $ 148 M israelIsrael
Madrigal Pharmaceuticals Madrigal Pharmaceuticals
MDGL
958 M $ 378.19 -4.68 % $ 8.48 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
67.8 K $ 1.2 -18.37 % $ 9.62 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
9.2 M $ 3.14 -9.13 % $ 188 M franceFrance
MeiraGTx Holdings plc MeiraGTx Holdings plc
MGTX
81.4 M $ 7.98 -1.97 % $ 642 M usaUSA
Teva Pharmaceutical Industries Limited Teva Pharmaceutical Industries Limited
TEVA
1.5 B $ 39.21 1.76 % $ 44.9 B israelIsrael
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
80 M $ 60.77 -0.96 % $ 1.64 B usaUSA
IDEAYA Biosciences IDEAYA Biosciences
IDYA
219 M $ 25.52 -2.48 % $ 2.26 B usaUSA
Protalix BioTherapeutics Protalix BioTherapeutics
PLX
52.7 M $ 2.89 -5.56 % $ 227 M israelIsrael
Foghorn Therapeutics Foghorn Therapeutics
FHTX
30.9 M $ 1.71 -3.93 % $ 108 M usaUSA
Ocugen Ocugen
OCGN
4.41 M $ 0.77 4.74 % $ 241 M usaUSA
Minerva Neurosciences Minerva Neurosciences
NERV
41.2 M $ 2.03 -4.25 % $ 17.2 M usaUSA
Neurocrine Biosciences Neurocrine Biosciences
NBIX
2.86 B $ 150.5 -3.89 % $ 15 B usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
32.6 M $ 26.12 -1.7 % $ 1.25 T franceFrance
Prothena Corporation plc Prothena Corporation plc
PRTA
9.68 M $ 8.12 -3.33 % $ 437 M usaUSA
Mereo BioPharma Group plc Mereo BioPharma Group plc
MREO
36.5 M $ 0.26 -5.45 % $ 207 M britainBritain
Maravai LifeSciences Holdings Maravai LifeSciences Holdings
MRVI
186 M $ 6.99 -2.85 % $ 1.01 B usaUSA
Lexicon Pharmaceuticals Lexicon Pharmaceuticals
LXRX
49.8 M $ 1.53 -8.68 % $ 555 M usaUSA
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
TAK
4.58 T $ 21.79 1.66 % $ 34.4 B japanJapan
Nurix Therapeutics Nurix Therapeutics
NRIX
84 M $ 12.88 -5.29 % $ 1.12 B usaUSA
Nkarta Nkarta
NKTX
115 K $ 1.14 1.34 % $ 84.3 M usaUSA
MacroGenics MacroGenics
MGNX
150 M $ 1.97 -0.76 % $ 124 M usaUSA
Protagonist Therapeutics Protagonist Therapeutics
PTGX
46 M $ 121.72 -2.2 % $ 7.74 B usaUSA
Novo Nordisk A/S Novo Nordisk A/S
NVO
309 B $ 37.8 -2.82 % $ 168 B danmarkDanmark